CSS
APLS

Cubist Systematic Strategies’s Apellis Pharmaceuticals APLS Stock Holding History

Cubist Systematic Strategies’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$6.78M Buy
+299,783
New +$6.99M 0.03% 789
2025
Q1 		– Sell
-191,687
Closed -$6.12M – 2830
2024
Q4 		$6.12M Buy
+191,687
New +$5.76M 0.04% 717
2024
Q2 		– Sell
-36,994
Closed -$1.68M – 2938
2024
Q1 		$2.17M Buy
36,994
+15,464
+72% +$986K 0.01% 1586
2023
Q4 		$1.29M Sell
21,530
-21,391
-50% -$1.09M 0.01% 1849
2023
Q3 		$1.63M Buy
42,921
+1,742
+4% +$76.5K 0.01% 1510
2023
Q2 		$3.75M Buy
41,179
+20,710
+101% +$1.79M 0.02% 1020
2023
Q1 		$1.35M Buy
+20,469
New +$1.18M 0.01% 1949
2022
Q4 		– Sell
-13,951
Closed -$953K – 4220
2022
Q3 		$953K Buy
+13,951
New +$826K 0.01% 2665
2022
Q2 		– Sell
-10,304
Closed -$524K – 4348
2022
Q1 		$524K Sell
10,304
-15,993
-61% -$706K ﹤0.01% 2506
2021
Q4 		$1.24M Sell
26,297
-7,549
-22% -$297K 0.01% 1753
2021
Q3 		$1.12M Buy
33,846
+27,262
+414% +$1.53M 0.01% 1433
2021
Q2 		$416K Sell
6,584
-14,847
-69% -$766K ﹤0.01% 2125
2021
Q1 		$920K Buy
21,431
+12,489
+140% +$591K 0.01% 1592
2020
Q4 		$511K Sell
8,942
-20,266
-69% -$857K 0.01% 1764
2020
Q3 		$881K Sell
29,208
-7,513
-20% -$224K 0.01% 1406
2020
Q2 		$1.2M Buy
36,721
+10,597
+41% +$340K 0.02% 1076
2020
Q1 		$700K Sell
26,124
-22,205
-46% -$788K 0.02% 1046
2019
Q4 		$1.48M Buy
48,329
+29,795
+161% +$825K 0.03% 919
2019
Q3 		$446K Buy
18,534
+18,449
+21,705% +$508K 0.01% 1350
2019
Q2 		$2K Sell
85
-12,518
-99% -$255K ﹤0.01% 2422
2019
Q1 		$246K Sell
12,603
-10,748
-46% -$169K 0.01% 1634
2018
Q4 		$308K Buy
+23,351
New +$358K 0.01% 1262

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Cubist Systematic Strategies's APLS Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Apellis Pharmaceuticals (APLS) in Q3 2025: 299,783 shares worth $6.78M. The stake represents 0.03% of the portfolio and ranks #789 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in APLS as recently as Q4 2024.

Cubist Systematic Strategies first reported a position in APLS in Q4 2018 and has held it in 22 quarters since. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

  • Cubist Systematic Strategies held 299,783 shares of Apellis Pharmaceuticals worth $6.78M as of Q3 2025.
  • Apellis Pharmaceuticals was a new Cubist Systematic Strategies position in Q3 2025.
  • Apellis Pharmaceuticals made up 0.03% of Cubist Systematic Strategies's portfolio in Q3 2025, its #789 holding.
  • Cubist Systematic Strategies first reported a position in Apellis Pharmaceuticals in Q4 2018 and has held it in 22 quarters since.
  • 273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.